Olema Oncology partners with Pfizer for breast cancer drug trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq poised to lead Wall St after Nvidia puts AI fears to rest
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil gains as traders weigh prospects of easing Middle East supply disruptions
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
Olema Pharmaceuticals (OLMA) latest collaboration could create future 'bidding war' - Oppenheimer
September 3, 2025 3:01 PM EDTOppenheimer analyst Matthew Biegler reiterated an Outperform rating and $22.00 price target on Olema Pharmaceuticals (NASDAQ: OLMA), saying the Pfizer collaboration could lead to a future bidding war for the company.
The analyst commented, "We had a chance to speak with Olema management after... More
